Shizuko Sei

2.7k total citations
73 papers, 1.9k citations indexed

About

Shizuko Sei is a scholar working on Oncology, Virology and Infectious Diseases. According to data from OpenAlex, Shizuko Sei has authored 73 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 23 papers in Virology and 21 papers in Infectious Diseases. Recurrent topics in Shizuko Sei's work include HIV Research and Treatment (23 papers), HIV/AIDS drug development and treatment (18 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Shizuko Sei is often cited by papers focused on HIV Research and Treatment (23 papers), HIV/AIDS drug development and treatment (18 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Shizuko Sei collaborates with scholars based in United States, Austria and Germany. Shizuko Sei's co-authors include Robert H. Shoemaker, Raveendra Dayam, Nouri Neamati, Tino W. Sanchez, Hiroaki Mitsuya, Ya-Qiu Long, Pim Brouwers, Qi Zhang, Kunio Nagashima and Ronald A. Lubet and has published in prestigious journals such as Journal of Clinical Investigation, Blood and The Journal of Immunology.

In The Last Decade

Shizuko Sei

71 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shizuko Sei United States 26 629 574 512 478 325 73 1.9k
Hiroo Hoshino Japan 29 458 0.7× 647 1.1× 746 1.5× 373 0.8× 868 2.7× 99 2.3k
Steven S. Good United States 21 952 1.5× 466 0.8× 739 1.4× 461 1.0× 178 0.5× 43 2.5k
Chih‐Tai Leu United States 17 883 1.4× 816 1.4× 1.1k 2.1× 454 0.9× 120 0.4× 25 2.2k
Stephen Oroszlan United States 19 285 0.5× 374 0.7× 828 1.6× 300 0.6× 404 1.2× 28 1.6k
Alexander Pasternak Netherlands 30 1.2k 1.9× 1.0k 1.8× 690 1.3× 268 0.6× 438 1.3× 88 2.5k
Robert Hamatake United States 33 593 0.9× 261 0.5× 1.6k 3.1× 223 0.5× 133 0.4× 76 3.1k
David J. Clanton United States 22 455 0.7× 560 1.0× 684 1.3× 190 0.4× 186 0.6× 37 1.4k
Alexander Zdanov United States 27 233 0.4× 199 0.3× 1.1k 2.1× 414 0.9× 775 2.4× 44 2.3k
Joseph A. Hollenbaugh United States 21 455 0.7× 647 1.1× 699 1.4× 218 0.5× 975 3.0× 31 2.1k
Stefania Capone Italy 29 396 0.6× 230 0.4× 650 1.3× 153 0.3× 581 1.8× 77 2.3k

Countries citing papers authored by Shizuko Sei

Since Specialization
Citations

This map shows the geographic impact of Shizuko Sei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shizuko Sei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shizuko Sei more than expected).

Fields of papers citing papers by Shizuko Sei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shizuko Sei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shizuko Sei. The network helps show where Shizuko Sei may publish in the future.

Co-authorship network of co-authors of Shizuko Sei

This figure shows the co-authorship network connecting the top 25 collaborators of Shizuko Sei. A scholar is included among the top collaborators of Shizuko Sei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shizuko Sei. Shizuko Sei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hussein, Usama Khamis, Tingting Mills, Lana A. Vornik, et al.. (2024). Preventive Treatment with a CD73 Small Molecule Inhibitor Enhances Immune Surveillance in K-Ras Mutant Pancreatic Intraepithelial Neoplasia. Cancer Prevention Research. 17(10). 457–470. 2 indexed citations
2.
Stanton, Sasha E., Philip E. Castle, Olivera J. Finn, Shizuko Sei, & Leisha A. Emens. (2024). Advances and challenges in cancer immunoprevention and immune interception. Journal for ImmunoTherapy of Cancer. 12(3). e007815–e007815. 12 indexed citations
3.
Sei, Shizuko, Sudhir Srivastava, Mark Steven Miller, et al.. (2024). NCI Resources for Cancer Immunoprevention Research. Cancer Immunology Research. 12(4). 387–392. 1 indexed citations
4.
Dragnev, Konstantin H., Ronald A. Lubet, Mark Steven Miller, et al.. (2023). Primary Prevention and Interception Studies in RAS-Mutated Tumor Models Employing Small Molecules or Vaccines. Cancer Prevention Research. 16(10). 549–560. 3 indexed citations
5.
Xiong, Donghai, Katie Palen, Bryon D. Johnson, et al.. (2023). Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention. npj Precision Oncology. 7(1). 108–108. 11 indexed citations
6.
Mazumdar, Abhijit, Jamal Hill, Jitesh D. Kawedia, et al.. (2022). Targeting the mTOR Pathway for the Prevention of ER-Negative Breast Cancer. Cancer Prevention Research. 15(12). 791–802. 4 indexed citations
7.
Kwan, Suet‐Ying, Peng Wei, Michelle I. Savage, et al.. (2022). Treatment Strategies and Mechanisms Associated with the Prevention of NASH-Associated HCC by a Toll-like Receptor 4 Inhibitor. Cancer Prevention Research. 16(1). 17–28. 5 indexed citations
8.
Zhang, Qi, Jing Pan, Donghai Xiong, et al.. (2021). Pulmonary Aerosol Delivery of Let‐7b microRNA Confers a Striking Inhibitory Effect on Lung Carcinogenesis through Targeting the Tumor Immune Microenvironment. Advanced Science. 8(17). e2100629–e2100629. 28 indexed citations
9.
Pan, Jing, Yao Chen, Qi Zhang, et al.. (2021). Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA. Communications Biology. 4(1). 906–906. 23 indexed citations
10.
Rajendran, Praveen, Wan Mohaiza Dashwood, Michelle I. Savage, et al.. (2020). Optimization of Erlotinib Plus Sulindac Dosing Regimens for Intestinal Cancer Prevention in an Apc-Mutant Model of Familial Adenomatous Polyposis (FAP). Cancer Prevention Research. 14(3). 325–336. 12 indexed citations
11.
Mohammed, Altaf, Mark Steven Miller, Ronald A. Lubet, et al.. (2019). Combination of Erlotinib and Naproxen Employing Pulsatile or Intermittent Dosing Profoundly Inhibits Urinary Bladder Cancers. Cancer Prevention Research. 13(3). 273–282. 8 indexed citations
12.
Pan, Jing, Qi Zhang, Katie Palen, et al.. (2019). Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator. EBioMedicine. 49. 72–81. 49 indexed citations
13.
Liu, Jinjing, Ching‐Lin Hsieh, Shizuko Sei, et al.. (2019). Proteomic characterization of outer membrane vesicles from gut mucosa-derived fusobacterium nucleatum. Journal of Proteomics. 195. 125–137. 53 indexed citations
14.
Nayar, Utthara, Jonathan Reichel, Gunkut Akar, et al.. (2017). Identification of a nucleoside analog active against adenosine kinase–expressing plasma cell malignancies. Journal of Clinical Investigation. 127(6). 2066–2080. 9 indexed citations
15.
Kirnbauer, Reinhard, George W. Buchman, Margaret C. Fisher, et al.. (2016). 426 cGMP production of a chimeric virus-like particle vaccine (RG1-VLP) for prevention of HPV-associated cancers. Journal of Investigative Dermatology. 136(9). S233–S233. 1 indexed citations
16.
Márquez, Víctor E., Stephen H. Hughes, Shizuko Sei, & Riad Agbaria. (2006). The history of N-methanocarbathymidine: The investigation of a conformational concept leads to the discovery of a potent and selective nucleoside antiviral agent. Antiviral Research. 71(2-3). 268–275. 55 indexed citations
17.
Dorjsuren, Dorjbal, Xulin Chen, Weimin Zhu, et al.. (2005). Chemical library screen for novel inhibitors of Kaposi's sarcoma-associated herpesvirus processive DNA synthesis. Antiviral Research. 69(1). 9–23. 31 indexed citations
18.
Stephen, Andrew G., Karen M. Worthy, Eric M. Towler, et al.. (2002). Identification of HIV-1 nucleocapsid protein: nucleic acid antagonists with cellular anti-HIV activity. Biochemical and Biophysical Research Communications. 296(5). 1228–1237. 47 indexed citations
19.
Sei, Shizuko, et al.. (2001). Protective effect of CCR5 Δ32 heterozygosity is restricted by SDF-1 genotype in children with HIV-1 infection. AIDS. 15(11). 1343–1352. 27 indexed citations
20.
Sei, Shizuko, Robert Yarchoan, Seiji Kageyama, et al.. (1992). Plasma HIV-1 Viremia in HIV-1 Infected Individuals Assessed by Polymerase Chain Reaction. AIDS Research and Human Retroviruses. 8(7). 1263–1270. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroo Hoshino Breakdown of academic impact, for papers by Steven S. Good Breakdown of academic impact, for papers by Chih‐Tai Leu Breakdown of academic impact, for papers by Stephen Oroszlan Breakdown of academic impact, for papers by Alexander Pasternak Breakdown of academic impact, for papers by Robert Hamatake Breakdown of academic impact, for papers by David J. Clanton Breakdown of academic impact, for papers by Alexander Zdanov Breakdown of academic impact, for papers by Joseph A. Hollenbaugh Breakdown of academic impact, for papers by Stefania Capone
Rankless by CCL
2026